These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
260 related items for PubMed ID: 22475657
1. [Study on in vitro susceptibility of Candida spp. isolated from blood culture]. Grandesso S, Sapino B, Mazzuccato S, Solinas M, Bedin M, D'Angelo M, Gion M. Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657 [Abstract] [Full Text] [Related]
2. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. González GM, Elizondo M, Ayala J. J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907 [Abstract] [Full Text] [Related]
5. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method. Matsumoto FE, Dias AL, Melhem MS, Szeszs MW, Auler ME, Ruiz LS, Gonçalves da Silva E, Gandra RF, Paula CR. Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562 [Abstract] [Full Text] [Related]
6. Antifungal susceptibility of Candida isolates at one institution. Katsuragi S, Sata M, Kobayashi Y, Miyoshi T, Yamashita Y, Neki R, Horiuchi C, Yamanaka K, Kamiya C, Iwanaga N, Tanaka H, Ikeda T, Yoshimatsu J. Med Mycol J; 2014 Dec; 55(1):E1-7. PubMed ID: 24682093 [Abstract] [Full Text] [Related]
7. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Dagi HT, Findik D, Senkeles C, Arslan U. Ann Clin Microbiol Antimicrob; 2016 May 31; 15(1):36. PubMed ID: 27245756 [Abstract] [Full Text] [Related]
10. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Marco F, Pfaller MA, Messer S, Jones RN. Antimicrob Agents Chemother; 1998 Jan 31; 42(1):161-3. PubMed ID: 9449278 [Abstract] [Full Text] [Related]
14. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC. Dan Med J; 2013 Nov 31; 60(11):B4698. PubMed ID: 24192246 [Abstract] [Full Text] [Related]
15. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. J Infect Chemother; 2009 Feb 31; 15(1):1-5. PubMed ID: 19280292 [Abstract] [Full Text] [Related]
17. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens. Ozçelik B, Kaynak F, Cesur S, Sipahi B, Sultan N. Jpn J Infect Dis; 2007 Sep 31; 60(5):302-4. PubMed ID: 17881873 [Abstract] [Full Text] [Related]
18. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents. Chen TC, Chen YH, Chen YC, Lu PL. Kaohsiung J Med Sci; 2012 Jun 31; 28(6):306-15. PubMed ID: 22632885 [Abstract] [Full Text] [Related]
19. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products. Soler L, Rodriguez JC, Belda S, Cremades R, Ruiz-Garcia M, Lopez P, Royo G. J Chemother; 2010 Aug 31; 22(4):283-4. PubMed ID: 20685636 [No Abstract] [Full Text] [Related]